Daniel P. McGough

Daniel P. McGough

Auto-generated profile, based on publicly available information

Daniel P. McGough

Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2022 in World Neurosurgery
Verified
Journal Article
Closed access
JFJonathan A Forbes
Jonathan A Forbes
PPPaolo Palmisciano
Paolo Palmisciano
DMDaniel McGough
Daniel McGough
CKChitra Kumar
Chitra Kumar
AHAhmed E. Hussein
Ahmed E. Hussein
JCJoseph Cheng
Joseph Cheng

24 August 2024 in Journal of Surgical Research
Verified
Journal Article
Open access
DMDaniel P. McGough
Daniel P. McGough
APAdam D. Price
Adam D. Price
JWJenna N. Whitrock
Jenna N. Whitrock
HHHussein Hariri
Hussein Hariri
SPSameer H. Patel
Sameer H. Patel
GWGregory C. Wilson
Gregory C. Wilson
Surgery followed by pathology-guided adjuvant therapy is standard treatment for colon cancer. Data from the FOxTROT clinical trial showed potential benefit of a 6-wk neoadjuvant chemotherapy (NACT) in T3/T4 patients. The present study evaluated real-world outcomes of neoadjuvant therapy in a national cohort of patients with resectable colon cancer. 169,120 patients with clinical stage I, II, or III colon cancer from the National Cancer Database registry were included. Patients were categorized as having received neoadjuvant therapy followed by surgery (NACT), surgery then adjuvant chemotherapy (AC), or surgery alone. Factors associated with treatment sequencing and outcomes were assessed. Of identified patients, 1.4% received NACT including 0.5% of stage I, 1.8% of stage II, and 3.0% of stage III. For stage I, 5-y overall survival (OS) was 74.7% after AC, 62.2% after NACT, and 76.4% after SA. For stage II, 5-y OS was 73.2% after AC, 66.8% after NACT, and 64.3% after SA. For stage III, 5-y OS was 67.3% after AC, 67.7% after NACT, and 42.4% after SA. Cox proportional-hazards model suggested NACT had worse outcomes versus AC in clinical stages I (hazard ratio [HR] = 1.59, 95% confidence interval [CI] 1.39-1.85, P < 0.01) and II (HR = 1.37, 95% CI 1.23-1.52, P < 0.01). In stage III, there was no difference in OS between NACT and AC (HR = 1.1, 95% CI 0.99-1.22, P = 0.05). In a real-world national cohort of patients with resectable colon cancer, NACT had no OS benefit over AC. Future studies should examine which subset of patients might benefit from neoadjuvant approaches.